Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
None of low 25(OH)D, high 25(OH)D, or deseasonalized (continuous) 25(OH)D concentration were significant predictors of progression to clinically definite multiple sclerosis, and none were retained in the predictive model.
Source: Progression to clinically definite multiple sclerosis according to demographic and environmental factors. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The Ausimmune Study was a population-based multi-centre incident case: control study designed to capture all incident first demyelinating event cases in four regions of Australia of differing latitude: Brisbane city (latitude 27°S), Newcastle city and surrounds (33°S), Geelong city and the Western Districts of Victoria (37°S) and the island of Tasmania (43°S).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis
Case-control study · Brain Communications · 2022
Original publication title
Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Understanding the predictors of progression from a first to a second demyelinating event (and formerly, a diagnosis of clinically definite multiple sclerosis) is important clinically. Previous studies have focused on predictors within a single domain, e.g. radiological, lacking prospective data across multiple domains. We tested a comprehensive set of personal, environmental, neurological, MRI and genetic characteristics, considered together, as predictors of progression from a first demyelinating event to clinically definite multiple sclerosis. Participants were aged 18 to 59 years and had a first demyelinating event during the study recruitment period (1 November 2003 to 31 December 2006) for the Ausimmune Study (n = 216) and had follow-up data to 2 to 3 years post-initial interview.
Detailed baseline data were available on a broad range of demographic and environmental factors, MRI, and genetic and viral studies. Follow-up data included confirmation of clinically definite multiple sclerosis (or not) and changes in environmental exposures during the follow-up period. We used multivariable logistic regression and Cox proportional hazards regression modelling to test predictors of, and time to, conversion to clinically definite multiple sclerosis. On review, one participant had an undiagnosed event prior to study recruitment and was excluded (n = 215).
Data on progression to clinically definite multiple sclerosis were available for 91.2% (n = 196); 77% were diagnosed as clinically definite multiple sclerosis at follow-up. Mean (standard deviation) duration of follow-up was 2.7 (0.7) years. The set of predictors retained in the best predictive model for progression from a first demyelinating event to clinically definite multiple sclerosis were as follows: younger age at first demyelinating event [adjusted odds ratio (aOR) = 0.92, 95% confidence interval (CI) = 0.87 to 0.97, per additional year of age); being a smoker at baseline (versus not) (aOR = 2.55, 95% CI 0.85 to 7.69); lower sun exposure at age 6 to 18 years (aOR = 0.86, 95% CI 0.74 to 1.00, per 100 kJ/m2 increment in ultraviolet radiation dose), presence (versus absence) of infratentorial lesions on baseline magnetic resonance imaging (aOR = 7.41, 95% CI 2.08 to 26.41); and single nucleotide polymorphisms in human leukocyte antigen (HLA)-B (rs2523393, aOR = 0.25, 95% CI 0.09 to 0.68, for any G versus A:A), TNFRSF1A (rs1800693, aOR = 5.82, 95% CI 2.10 to 16.12, for any C versus T:T), and a vitamin D-binding protein gene (rs7041, aOR = 3.76, 95% CI 1.41 to 9.99, for any A versus C:C).
The final model explained 36% of the variance. Predictors of more rapid progression to clinically definite multiple sclerosis (Cox proportional hazards regression) were similar. Genetic and magnetic resonance imaging characteristics as well as demographic and environmental factors predicted progression, and more rapid progression, from a first demyelinating event to a second event and clinically definite multiple sclerosis.
Chapman et al. report that in a cohort of people with a first demyelinating event, younger age, smoking, low sun exposure, infratentorial lesions on MRI, and genes in HLA, vitamin D-binding protein, and tumour necrosis factor receptor 1A predicted faster progression to clinically definite multiple sclerosis over 2 to 3 years.
Authors’ abstract
Abstract
Understanding the predictors of progression from a first to a second demyelinating event (and formerly, a diagnosis of clinically definite multiple sclerosis) is important clinically. Previous studies have focused on predictors within a single domain, e.g. radiological, lacking prospective data across multiple domains. We tested a comprehensive set of personal, environmental, neurological, MRI and genetic characteristics, considered together, as predictors of progression from a first demyelinating event to clinically definite multiple sclerosis. Participants were aged 18 to 59 years and had a first demyelinating event during the study recruitment period (1 November 2003 to 31 December 2006) for the Ausimmune Study (n = 216) and had follow-up data to 2 to 3 years post-initial interview.
Detailed baseline data were available on a broad range of demographic and environmental factors, MRI, and genetic and viral studies. Follow-up data included confirmation of clinically definite multiple sclerosis (or not) and changes in environmental exposures during the follow-up period. We used multivariable logistic regression and Cox proportional hazards regression modelling to test predictors of, and time to, conversion to clinically definite multiple sclerosis. On review, one participant had an undiagnosed event prior to study recruitment and was excluded (n = 215).
Data on progression to clinically definite multiple sclerosis were available for 91.2% (n = 196); 77% were diagnosed as clinically definite multiple sclerosis at follow-up. Mean (standard deviation) duration of follow-up was 2.7 (0.7) years. The set of predictors retained in the best predictive model for progression from a first demyelinating event to clinically definite multiple sclerosis were as follows: younger age at first demyelinating event [adjusted odds ratio (aOR) = 0.92, 95% confidence interval (CI) = 0.87 to 0.97, per additional year of age); being a smoker at baseline (versus not) (aOR = 2.55, 95% CI 0.85 to 7.69); lower sun exposure at age 6 to 18 years (aOR = 0.86, 95% CI 0.74 to 1.00, per 100 kJ/m2 increment in ultraviolet radiation dose), presence (versus absence) of infratentorial lesions on baseline magnetic resonance imaging (aOR = 7.41, 95% CI 2.08 to 26.41); and single nucleotide polymorphisms in human leukocyte antigen (HLA)-B (rs2523393, aOR = 0.25, 95% CI 0.09 to 0.68, for any G versus A:A), TNFRSF1A (rs1800693, aOR = 5.82, 95% CI 2.10 to 16.12, for any C versus T:T), and a vitamin D-binding protein gene (rs7041, aOR = 3.76, 95% CI 1.41 to 9.99, for any A versus C:C).
The final model explained 36% of the variance. Predictors of more rapid progression to clinically definite multiple sclerosis (Cox proportional hazards regression) were similar. Genetic and magnetic resonance imaging characteristics as well as demographic and environmental factors predicted progression, and more rapid progression, from a first demyelinating event to a second event and clinically definite multiple sclerosis.
Chapman et al. report that in a cohort of people with a first demyelinating event, younger age, smoking, low sun exposure, infratentorial lesions on MRI, and genes in HLA, vitamin D-binding protein, and tumour necrosis factor receptor 1A predicted faster progression to clinically definite multiple sclerosis over 2 to 3 years.
Publication and source details
Original title: Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis
Caron Chapman; Robyn M Lucas; Anne-Louise Ponsonby; Bruce Taylor; Ausimmune Investigator Group ChapmanCaronDrCoulthardAlanProfDearKeithProfDwyerTerryProfKilpatrickTrevorProfLucasRobynProfMcMichaelTonyProfPenderMichaelProfPonsonbyAnne-LouiseProfTaylorBruceProfValeryPatricia CProfvan der MeiIngridA/ProfWilliamsDavidDr
Brain Communications · 2022
Correspondence to: Prof Robyn Lucas National Centre for Epidemiology and Population Health The Australian National University Canberra 2601, Australia E-mail: robyn.lucas@anu.edu.auCaron Chapman and Robyn M Lucas joint first authors.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:43:32.483302+00:00
DOI: 10.1093/braincomms/fcac181 · PMC9308470